PlainRecalls
FDA Drug Moderate Class II Ongoing

Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, a) 100 ct. bottle (NDC 70010-492-01) and 500 ct. bottle (NDC 70010-492-05), Manufactured for: Granules Pharmaceutical Inc., Chantilly, VA, Manufactured by: Granules India Limited, Hyderabad - 500-081, India

Reported: July 22, 2020 Initiated: July 3, 2020 #D-1386-2020

Product Description

Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, a) 100 ct. bottle (NDC 70010-492-01) and 500 ct. bottle (NDC 70010-492-05), Manufactured for: Granules Pharmaceutical Inc., Chantilly, VA, Manufactured by: Granules India Limited, Hyderabad - 500-081, India

Reason for Recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Details

Units Affected
a) 476,073 bottles; b) 2,100 bottles
Distribution
US Nationwide
Location
Chantilly, VA

Frequently Asked Questions

What product was recalled?
Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, a) 100 ct. bottle (NDC 70010-492-01) and 500 ct. bottle (NDC 70010-492-05), Manufactured for: Granules Pharmaceutical Inc., Chantilly, VA, Manufactured by: Granules India Limited, Hyderabad - 500-081, India. Recalled by Granules Pharmaceuticals Inc. Units affected: a) 476,073 bottles; b) 2,100 bottles.
Why was this product recalled?
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Which agency issued this recall?
This recall was issued by the FDA Drug on July 22, 2020. Severity: Moderate. Recall number: D-1386-2020.